Dihydroorotate dehydrogenase inhibitor F901318 has potent in vitro activity against Scedosporium species and Lomentospora prolificans

F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase

(2016) Jason D. Oliver et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Epidemiology of Invasive Mold Infections in Lung Transplant Recipients

(2014) C. T. Doligalski et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Susceptibility and Diversity in the Therapy-Refractory Genus Scedosporium

(2014) M. Lackner et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Proposed nomenclature for Pseudallescheria, Scedosporium and related genera

(2014) Michaela Lackner et al.   FUNGAL DIVERSITY

Epidemiology, clinical manifestations, and outcomes ofScedosporiuminfections among solid organ transplant recipients

(2014) L.S. Johnson et al.   Transplant Infectious Disease

In vitro activity of miltefosine as a single agent and in combination with voriconazole or posaconazole against uncommon filamentous fungal pathogens

(2013) C. Biswas et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Scedosporium prolificansOsteomyelitis in an Immunocompetent Child Treated with a Novel Agent, Hexadecylphospocholine (Miltefosine), in Combination with Terbinafine and Voriconazole: A Case Report

(2009) Alison M. Kesson et al.   CLINICAL INFECTIOUS DISEASES

Infections Caused by Scedosporium spp.

(2008) K. J. Cortez et al.   CLINICAL MICROBIOLOGY REVIEWS